Published January 1, 2026

Drug Price Increases 2026: What Patients Need to Know

Drug price increases 2026 are already reshaping the cost of care in the United States. On January 1, many major pharmaceutical companies raised prices on hundreds of medicines. These changes came even as strong political pressure and public criticism were directed at high drug costs. Patients, doctors, and insurers are now assessing what these new prices will mean for treatment access and affordability.

Why Drug Price Increases 2026 Are Drawing Attention 💊

Drug price increases 2026 are especially controversial because they arrive while federal leaders are calling for lower health costs. The administration had urged manufacturers to cut or at least freeze prices. Instead, several large companies raised list prices on a wide range of products.

Most of these changes affect brand‑name drugs that already carry high price tags. They include vaccines, cancer therapies, and common chronic disease treatments. While actual out‑of‑pocket costs can be reduced by insurance, rebates, or discounts, the list price still matters. It helps shape premiums, deductibles, and what uninsured patients must pay.

Major Companies Raising Prices in 2026 🏭

A wave of drug price increases 2026 has been led by some of the world’s largest manufacturers. Among the most active companies:

• Pfizer
• Sanofi
• Novartis
• Bristol Myers Squibb
• Johnson & Johnson (and Janssen)
• Merck & Co.
• AbbVie
• Eli Lilly

Most companies applied multiple hikes across their portfolios. In many cases, prices were raised by around 5%. Some increases were smaller, while a few products saw higher changes. The overall trend, however, points clearly upward.

Key Drugs Seeing Higher Prices in 2026 📈

Below is a sample list of notable products reported to have higher list prices in 2026. These examples show how broad the increases are across different conditions.

Pfizer

• Prevnar 13 / Prevnar 20 – Pneumococcal vaccines used to prevent serious infections
• Ibrance – Breast cancer therapy
• Xeljanz – Rheumatoid arthritis and other inflammatory disease treatment
• Eliquis (with partner Bristol Myers Squibb) – Blood thinner used for stroke prevention

Sanofi

• Dupixent – Treatment for eczema, asthma, and chronic sinus disease
• Lantus – Long‑acting insulin for diabetes
• Toujeo – Concentrated basal insulin
• Aubagio – Oral medication for multiple sclerosis

Novartis

• Gleevec – Leukemia treatment (some legacy pricing changes remain in effect)
• Cosentyx – Psoriasis and psoriatic arthritis biologic
• Entresto – Heart failure medicine
• Tasigna – Another targeted leukemia therapy

Bristol Myers Squibb

• Eliquis (with Pfizer) – Widely used anticoagulant
• Opdivo – Immunotherapy for several cancers
• Revlimid (through a Celgene acquisition) – Multiple myeloma treatment

Johnson & Johnson / Janssen

• Stelara – Psoriasis and Crohn’s disease biologic
• Imbruvica – Blood cancer therapy
• Xarelto – Blood thinner for clot prevention

Merck & Co.

• Keytruda – Blockbuster cancer immunotherapy
• Gardasil 9 – HPV vaccine
• Januvia – Type 2 diabetes medicine

AbbVie

• Humira – Autoimmune therapy for arthritis, Crohn’s, and other conditions
• Imbruvica (co‑promoted) – Cancer treatment
• Skyrizi – Psoriasis biologic

Eli Lilly

• Trulicity – Diabetes drug that also supports weight loss
• Taltz – Psoriasis and arthritis biologic
• Basaglar – Insulin glargine product

This list is not exhaustive. However, it shows that price hikes are touching multiple therapeutic areas, including cancer, immunology, cardiovascular disease, and vaccines.

Why Are Prices Rising Despite Political Pressure? 🏛️

Many people are asking why drug price increases 2026 are happening under such intense scrutiny. Several reasons are often cited by manufacturers:

• They argue that research and development costs are high and must be recovered.
• They claim that rebates to pharmacy benefit managers and insurers reduce their net revenue.
• They say that modest, regular hikes are needed to support future innovation.

At the same time, advocates and health policy experts remain skeptical. They note that:

• Many drugs seeing higher prices have been on the market for years.
• Development costs were already recouped long ago in some cases.
• Net prices may have fallen in a few contracts, yet list prices keep climbing.

Because of this tension, pressure on the industry has not eased. In fact, the gap between public demands and corporate decisions appears to be widening.

How These Increases Affect Patients and Insurance 🧾

Patients may not feel every list price change right away. Still, the impact is likely to be seen over time through:

• Higher deductibles and premiums
• Larger copays for some brand‑name drugs
• Increased financial stress for uninsured or underinsured people

Those with high‑deductible plans can be hit particularly hard. They often pay close to the list price until their deductible is met. Patients on multiple brand‑name drugs may see their annual costs rise significantly.

Insurers and employers usually respond by tightening formularies. This may be done by:

• Preferring cheaper alternatives when available
• Requiring prior authorization
• Adding step therapy rules before high‑cost drugs are approved

As a result, access can be delayed or restricted, even when a treatment is medically appropriate.

What Patients Can Do in Response 🧭

In the face of drug price increases 2026, several strategies can help reduce the burden:

• Ask about generics or biosimilars when they exist
• Review your plan’s formulary before refilling prescriptions
• Apply for manufacturer patient assistance programs if eligible
• Compare pharmacy prices and use accredited discount programs
• Discuss therapeutic alternatives with your doctor early

These steps can not eliminate every added cost, but they may lessen the financial strain.

The Road Ahead for US Drug Pricing 🔍

Pressure on drugmakers is expected to continue through 2026 and beyond. Lawmakers are weighing further reforms, including stronger negotiation powers and penalties for excessive annual hikes. At the same time, companies are defending their pricing strategies while rolling out new high‑cost therapies.

As debates intensify, patients remain caught in the middle. The latest drug price increases 2026 underscore how urgently the United States needs a clearer, more sustainable approach to balancing innovation with affordability.